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Background: DNA methylation is a complex epigenetic marker that can be analyzed using a wide variety of
methods. Interpretation and visualization of DNA methylation data can mask complexity in terms of methylation
status at each CpG site, cellular heterogeneity of samples and allelic DNA methylation patterns within a given
DNA strand. Bisulfite sequencing is considered the gold standard, but visualization of massively parallel sequencing
results remains a significant challenge.
Findings: We created a program called Methpat that facilitates visualization and interpretation of bisulfite sequencing
data generated by massively parallel sequencing. To demonstrate this, we performed multiplex PCR that targeted 48
regions of interest across 86 human samples. The regions selected included known gene promoters associated with
cancer, repetitive elements, known imprinted regions and mitochondrial genomic sequences. We interrogated a range
of samples including human cell lines, primary tumours and primary tissue samples. Methpat generates two forms of
output: a tab-delimited text file for each sample that summarizes DNA methylation patterns and their read counts for
each amplicon, and a HTML file that summarizes this data visually. Methpat can be used with publicly available whole
genome bisulfite sequencing and reduced representation bisulfite sequencing datasets with sufficient read depths.
Conclusions: Using Methpat, complex DNA methylation data derived from massively parallel sequencing can
be summarized and visualized for biological interpretation. By accounting for allelic DNA methylation states
and their abundance in a sample, Methpat can unmask the complexity of DNA methylation and yield further
biological insight in existing datasets.
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DNA methylation can be analyzed using a wide range of
methods [1], with bisulfite sequencing considered the
current gold standard. Current technologies such as
whole genome bisulfite sequencing (WGBS) and reduced
representation bisulfite sequencing (RRBS) provide un-
precedented detail of methylation patterns throughout
the genome, but the complexity of DNA methylation
patterns is masked when simple summary metrics are
used. For example, most studies of DNA methylation* Correspondence: alex.dobrovic@onjcri.org.au
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masks allelic patterns when interpreting the data. We
have developed Methpat, a tool that summarizes and
visualizes complex DNA methylation data collected by
massively parallel sequencing of bisulfite DNA [2].
Using this tool, the DNA methylation state of individual
CpG sites and the abundance of allelic patterns can be
visualized [3]. Furthermore, by measuring the abun-
dance of allelic DNA methylation patterns, cellular hetero-
geneity in methylation patterns can now be explored [4].
The utility of Methpat was demonstrated by measur-
ing DNA methylation in 86 samples (Table 1) across 48
regions of interest (Table 2). This was achieved by using
multiplex PCR on bisulfite converted DNA followed by
massively parallel sequencing using an Illumina MiSeqis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Human Samples used in this study
Sample Name Description GEO Accession
293 HEK-293 embryonic kidney cell line. ATCC CRL1573 GSE67856
40424 Normal fibroblast cell line GSE67856
910046 Normal fibroblast cell line GSE67856
12A-CD19 Normal Fluorescent Activated Cell Sorted (FACS) CD19 positive bone marrow cells from individual 12A GSE67856
12A-CD33 Normal Fluorescent Activated Cell Sorted (FACS) CD33 positive bone marrow cells from individual 12A GSE67856
12A-CD34 Normal Fluorescent Activated Cell Sorted (FACS) CD34 positive bone marrow cells from individual 12A GSE67856
12A-CD45 Normal Fluorescent Activated Cell Sorted (FACS) CD45 positive bone marrow cells from individual 12A GSE67856
6-MDA453 MDA-MB-453 metastatic breast cancer cell line. ATCC HTB-131 GSE67856
6C-CD19 Normal Fluorescent Activated Cell Sorted (FACS) CD19 positive bone marrow cells from individual 6C GSE67856
6C-CD33 Normal Fluorescent Activated Cell Sorted (FACS) CD33 positive bone marrow cells from individual 6C GSE67856
6C-CD34 Normal Fluorescent Activated Cell Sorted (FACS) CD34 positive bone marrow cells from individual 6C GSE67856
6C-CD45 Normal Fluorescent Activated Cell Sorted (FACS) CD45 positive bone marrow cells from individual 6C GSE67856
9A-CD19 Normal Fluorescent Activated Cell Sorted (FACS) CD19 positive bone marrow cells from individual 9A GSE67856
9A-CD33 Normal Fluorescent Activated Cell Sorted (FACS) CD33 positive bone marrow cells from individual 9A GSE67856
9A-CD34 Normal Fluorescent Activated Cell Sorted (FACS) CD34 positive bone marrow cells from individual 9A GSE67856
9A-CD45 Normal Fluorescent Activated Cell Sorted (FACS) CD45 positive bone marrow cells from individual 9A GSE67856
9A-Whole-Blood Whole blood sample from individual 9A GSE67856
BRL Normal lymphoblast cell line. GSE67856
CaCo Caco2 Colon cancer cell line. ATCC HTB37 GSE67856
DG75 Lymphoblast cancer cell line. ATCC CRL-2625 GSE67856
EKVX Cancer Cell Line GSE67856
HELA Cancer cell line. ATCC CCL-2 GSE67856
HEPG2 Liver cancer cell line. ATCC HB-8065 GSE67856
HT1080 Cancer cell line. ATCC CCL121 GSE67856
HTB22-Col MCF7 breast cancer cell line. ATCC HTB22 GSE67856
JWL Normal lymphoblast cell line. GSE67856
K562 CML cancer cell line. ATCC CCL-243 GSE67856
Sample29 Cell Line GSE71804
MB231BAG Breast cancer cell line. ATCC HTB-26 GSE67856
MCF7 Breast cancer cell line. ATCC HTB22 GSE67856
NALM6 Leukaemia cell line. ACC 128 GSE67856
NCCIT Embryonic carcinoma cell line. ATCC CRL-2073 GSE67856
OVCAR8 Cancer cell line GSE67856
SKNAS Neuroblastoma cancer cell line. ATCC CRL2137 GSE67856
U231 Cancer cell line GSE67856
Sample1 Human normal colon tissue GSE71804
Sample2 Human colon tumor GSE71804
Sample3 Human normal colon tissue GSE71804
Sample4 Human colon tumor GSE71804
Sample5 Human normal colon tissue GSE71804
Sample6 Human colon tumor GSE71804
Sample7 Human normal colon tissue GSE71804
Sample8 Human colon tumor GSE71804
Sample9 Human normal colon tissue GSE71804
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Table 1 Human Samples used in this study (Continued)
Sample10 Human colon tumor GSE71804
Sample11 Human normal colon tissue GSE71804
Sample12 Human colon tumor GSE71804
Sample13 Pooled human cancer and blood cell DNA GSE71804
Sample14 Pooled human cancer and blood cell DNA GSE71804
Sample15 Pooled human cancer and blood cell DNA GSE71804
Sample16 Pooled human cancer and blood cell DNA GSE71804
Sample17 Pooled human cancer and blood cell DNA GSE71804
Sample18 Pooled human cancer and blood cell DNA GSE71804
Sample19 Artificially methylated human DNA GSE71804
Sample20 Artificially methylated human DNA GSE71804
Sample21 Artificially methylated human DNA GSE71804
Sample22 Artificially methylated human DNA GSE71804
Sample23 Artificially methylated human DNA GSE71804
Sample24 Artificially methylated human DNA GSE71804
Sample25 Human leukemia cell line GSE71804
Sample26 Human leukemia cell line GSE71804
Sample27 Human leukemia cell line GSE71804
Sample28 Human leukemia cell line GSE71804
468-C1-3-9_S40 MDA-468 cell line, control 1 GSE71804
468-C2-3-9_S48 MDA-468 cell line, control 2 GSE71804
468-S1-3-9_S56 MDA-468 cell line + EGF 1 GSE71804
468-S2-3-9_S64 MDA-468 cell line + EGF 2 GSE71804
ET-C1-3-9_S71 PMC42-ET cell line, control 1 GSE71804
ET-C2-3-9_S79 PMC42-ET cell line, control 2 GSE71804
ET-S1-3-9_S87 PMC42-ET cell line, +EGF 1 GSE71804
ET-S2-3-9_S95 PMC42-ET cell line, +EGF 2 GSE71804
LA-C1-3-9_S8 PMC42-LA cell line, control 1 GSE71804
LA-C3-3-9_S16 PMC42-LA cell line, control 2 GSE71804
LA-S1-3-9_S24 PMC42-LA cell line, +EGF 1 GSE71804
LA-S2-3-9_S32 PMC42-LA cell line, +EGF 2 GSE71804
PMC42ET-72-C_S31 PMC42-ET cell line, control 72 h GSE71804
PMC42ET-72 h-EGF_S39 PMC42-ET cell line, +EGF 72 h GSE71804
PMC42ET-9d-C_S47 PMC42-ET cell line, control 9 days GSE71804
PMC42ET-9d-EGF_S55 PMC42-ET cell line, +EGF 9 days GSE71804
PMC42ET-9d-TGFb_S63 PMC42-ET cell line, +TGFb 9 days GSE71804
PMC42LA-72 h-C_S86 PMC42-LA cell line, control 72 h GSE71804
PMC42LA-72 h-EGF_S94 PMC42-LA cell line, +EGF 72 h GSE71804
PMC42LA-9d-C_S7 PMC42-LA cell line, control 9 days GSE71804
PMC42LA-9d-EGF_S15 PMC42-LA cell line, +EGF 9 days GSE71804
PMC42LA-9d-TGFb_S23 PMC42-LA cell line, +TGFb 9 days GSE71804
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was indexed and pooled at equimolar concentrations
into a single library pool for sequencing. Data has
been deposited into GEO with reference identifiersGSE67856 [5] and GSE71804 [6]. A panel of breast
cancer cell lines treated with epidermal growth factor
and transforming growth factor beta were also ana-
lyzed in parallel [7].
Table 2 Bisulfite PCR primers used in this study
Primer name Primer sequence Primer Tm Genomic location (hg38)
mandatory01_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGAAGTTTGGTYGTTGYGTTTTTAT 60.1–62.9
mandatory01_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGRAAACCRCTCRCRAAATACCCTA 57.6–64.6 chr4:154710460-154710544
mandatory02_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTAGYGGAGTTTAAGGGTTAGTGT 59.2–60.9
mandatory02_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACRAAACRCACRTACRTATATTTATA 56.3–62.1 chr1:110052409-110052486
mandatory03_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGTTTGTTAGTTAGTTTTAGGTTTTTTAAT 59.8
mandatory03_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCTACCAAATTTCTATTACAAACCAAA 60.8 chr4:7526639-7526703
mandatory04_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGATTTGGTTTYGAGAGTTTGGATTTT 60.1–61.7
mandatory04_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAAAACCRCACACCTAAACACTTAAA 60.1–61.7 chr2:164593225-164593299
mandatory05_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGGAATTTTGAGATTTTTAAAAGTTTTTTT 59.8
mandatory05_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATAAAAACAACAAATACCACTTCCTAAA 59.9 chr2:9518296-9518358
mandatory06_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTGYGTYGATTTTGGTTTTGGTTAT 57.6–60.9
mandatory06_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCRACCCCTCCCAAATCCTAAAA 60.1–62.1 chr17:80709100-80709203
mandatory07_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTTAGAGGAGAYGTTTTAGTTTTT 59.2–60.9
mandatory07_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAATTCCAAAAAACRTCAATCACAATAA 59.9–61.5 chr3:142837969-142838050
mandatory08_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTTAAGAGGAGTTTGTTTTGTTTTAT 60.8
mandatory08_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTTCACTAAAAAACCTCACTCCCTA 60.9 chr7:140218100-140218192
mandatory09_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTTTTAGAGTGTTTTTGGTTTTATTATTTTT 60.2
mandatory09_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTATTTACCCCTAAAAATACCCTTTATA 59.2 chr7:26206542-26206614
mandatory10_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGAAGTTGAAGTGAGAATGTGATT 60.3
mandatory10_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAATACCCATACAAACTATCTACACAA 60.1 chr7:3025554-3025664
mandatory11_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTATATAAAAATTATTAAGAATTTTATTGTTTTGT 58.5
mandatory11_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAATATAACCAAAATCCAAATAACACTAA 58.2 chr7:138229946-138230021
mandatory12_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGYGGYGTTTGATGGATTTGGTTT 59.2–62.9
mandatory12_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTTAATATAACCTAAACCCATATACTA 59.2 chr2:42275714-42275789
mandatory13_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTAGATTATGTTAAGGATTTTGGAAAT 59.2
mandatory13_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTATACTATCAACACCCATTACTTAA 60.8 chr15:100249155-100249220
mandatory14_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTAAATTAGATGAGGTATAGTAGATTATAT 59.2
mandatory14_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAACTCTATCTCAAACTTCAAAAAATA 59.2 chr4:147557821-147557938
mandatory15_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTTGGGGGATAGTTTTGGGTAT 60.1
mandatory15_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTACAACCTCCTACAAAAAAACCCTA 60.9 chr17:75369174-75369252
mandatory16_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATATTTTTAATTTAATTTGAAGGTTTATTGT 57.8












Table 2 Bisulfite PCR primers used in this study (Continued)
h19_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATACRAAAAAAACCCACAATAAACTTAATA 59.8–61 chr11:2017873-2018050
mest_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTTTTGTTTTTTTAATTGTGTTTATTGTTT 60.2
mest_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTAACCACTATAACCAAAATTACACAAAA 59.9 chr7:130131098-130131299
xist_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTAGTAATTTAGTATTGTTTATTTTATTTTTTT 59
xist_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATAACRAACCTCTTTATCTTTACTATATA 59.2–60.5 chrX:73070975-73071183
runx3_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTAGAYGTTYGGAGTTTTAGGGT 58.3–62
runx3_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCRACAACCCCAACTTCCTCTA 59.5–61.2 chr1:25256022-25256153
rarb_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAATTTTTTTATGYGAGTTGTTTGAGGAT 59.9–61.5
rarb_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTCCTTCCAAATAAATACTTACAAAAAA 59.9 chr3:25469822-25469959
mlh1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGYGGGAGGTTATAAGAGTAGGGTT 60.9–62.9
mlh1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATACRAAATATCCAACCAATAAAAACAAAA 59.8–61 chr3:37034573-37034734
rassf1a_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTTTTYGTAGTTTAATGAGTTTAGGTTTT 60.5–62.1
rassf1a_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAATCCCTACACCCAAATTTCCATTA 60.9 chr3:50378200-50378398
apc_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGAGAGAAGTAGTTGTGTAAT 60.3
apc_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCATTCTATCTCCAATAACACCCTAA 60.9 chr5:112073447-112073596
cdkn2a_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTTTGTTTTTTAAATTTTTTGGAGGGAT 59.2
cdkn2a_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCCAACCTAAAACRACTTCAAAAATA 60.1–61.7 chr9:21974960-21975097
dapk1_p1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTYGGAGTGTGAGGAGGATAGT 60.9–62.9
dapk1_p1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGRACRACRAAAACACAACTAAAAAATAAATA 58.5–62.6 chr9:90112783-90112938
dapk1_p2_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGYGGAGGGATYGGGGAGTTTTT 62.1–65.5
dapk1_p2_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCRCCTTAACCTTCCCAATTA 63.6–65.2 chr9:90112991-90113144
dapk1_i1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGAGGYGGGGAGGTTAGTTAT 61.2–63.2
dapk1_i1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAATAAAAAAAAACACCCTTTATTAAAACTAA 59.8 chr9:90113588-90113759
gstp1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTGGGAAAGAGGGAAAGGTTTTT 60.3
gstp1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGRCRACCTCCRAACCTTATAAAAATAA 58.4–62.9 chr11:67351064-67351273
cdh1_snp_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTTTAGTAATTTTAGGTTAGAGGGTT 59.2
cdh1_snp_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAAAATAAATACRTAACTACAACCAAATAAA 59–60.2 chr16:68771006-68771197
cdh1_3ê_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTYGGAATTGTAAAGTATTTGTGAGT 60.1–61.7
cdh1_3ê_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATCAAAAAATCCRAAATACCTACAACAA 59.5–61.5 chr16:68771201-68771385
brca1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTAGTTATTTGAGAAATTTTATAGTTTGTT 59





















foxe3_2_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACRCAAAATATACTCCAAACCAAAATA 59.9–61.5 chr1
foxp3_1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTGGGTTTAGGGTTTTATTTGTAGT 59.2
foxp3_1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACCCAAAACCTCAAACCTACTAAA 60.3 chrX
foxp3_2_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTTTGGGGATGGGTTAAGGGTT 60.9
foxp3_2_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAACCAATACCTACTTTAACCAAAAA 60.1 chrX
tlx3_1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTYGGTTTAAGAAAGATGATATAGAGTT 59.9–61.5
tlx3_1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCCATCCTAAACRAACRAAAAAACTAA 59.2–62.1 chr5
tlx3_2_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGYGTTAGTTATTTGGGAGGGTTT 59.2–60.9
tlx3_2_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACRCTAAACTCAAATTCACACTATAAA 59.5–61.5 chr5
uniq_noCG_1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGTTATGTAGTTTTAGTTAGAAGTTT 59.2
uniq_noCG_1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAATCTAAATTTTAACACCTAAAACTATTTTAA 59.8 chr5
uniq_noCG_2_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATATGAAAGGTTGGTTTTATTGTTGAAT 59.9
uniq_noCG_2_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAAATAAACTTAATAACTCTACTCTTATATA 59 chr5
mgmt_1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTTGAGTTAGGTTTTGGTAGTGTT 60.3
mgmt_1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTAATACCRCTCCCCTAATCAAAA 60.3–62 chr10
mgmt_2_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGGTAGTTTYGAGTGGTTTTGT 59.2–60.9
mgmt_2_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACTAAACAACACCTAAAAAACACTTAA 59.9 chr10
mito_1_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTATTTATTTTTAATAGTATATAGTATATAAAGTT 58.5
mito_1_plus_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACTTTAACTACCCCCAAATATTATAA 58.4 chrM
mito_2_plus_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATGATTTTTAATAGGGGTTTTTTTAGTTT 59.2
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version efficiency with very low non-CpG Cs in reads.
An additional amplicon that corresponded to a sequence
containing no CpG sites was also included as a control,
from which all cytosines were observed to have con-
verted to thymidine residues [1].
The data included here are the Sequence Read Arch-
ive files generated from our experiment. These have
been aligned onto the hg38 reference genome using
Bismark v0.9.0, from which a BAM file for each sample
is generated. Using the Bismark_methylation_extractor
command, the methylation status of cytosine residues
within each read is output to a tab-delimited file. Methpat
then operates on this output file to generate both a sum-
marized tab-delimited file of read pattern counts and a
HTML file for visualization. We have included the
BAM files, Bismark_methylation_extractor output files
and Methpat output files as supporting data. Methpat
requires a Browser Extensive Data (BED)-format-like
file that contains the coordinates for each amplicon
of interest, their size and their primer lengths to ex-
tract and summarize DNA methylation pattern counts.
The flow of data is summarized in Fig. 1.
Our data has the potential to be used to investigate
co-methylation [8], given the unprecedented depth of
coverage of the amplicons investigated even in a sin-
gle MiSeq run. We have interrogated a variety of re-
gions of the genome including repetitive elements and
the mitochondrial genome, which remain a challenge
for most short read aligners. The interpretation of DNA
methylation at repetitive sequence elements has always
been a challenge and they are assumed to be methylated
[9]. However, the dynamics of repetitive element DNAFig. 1 Flow of data towards visualization via Methpat. Raw fastq files a
reference is prepared for Bismark using Bismark_genome_preparation w
fastq files to generate BAM alignment files. c Bismark_methylation_extra
in every aligned read and outputs a tab-delimited file that Methpat op
file containing information for each amplicon of interest. This includes
lengths for each amplicon. The output of Methpat is a summary tab-d
of the amplicons of interest and an HTML file for visualization and pubmethylation in cancer [10] and development [11] remain
areas of interest that can now be properly interpreted with
massively parallel sequencing and visualization tools such
as Methpat.Availability of software and requirements
Project name: Methpat
Project home page: http://bjpop.github.io/methpat/
Operating system(s): any POSIX-like operating system
(i.e.: Linux, OS X)
Programming language: Python 2.7, HTML and Javascript
Other requirements: Web Browser to view visualization
output (HTML file). Suggested browsers include Firefox,
Chrome or Safari. Methpat requires output files derived
by Bismark (http://www.bioinformatics.babraham.ac.uk/
projects/bismark/) and the Bismark_methylation_extrac-
tor command. Methpat can be accessed directly from
http://bjpop.github.io/methpat/. With further instruc-
tions found at the URL.
License: 3-clause BSD License
Any restrictions to use by non-academics: None
A flow diagram of analytical requirements and files
can be found in Fig. 1.Availability of supporting data and materials
Sequence files associated with main research publication
deposited in GEO, GSE67856 [5]. Remaining files are de-
posited in GEO, GSE71804 [6].
BAM files, bismark_methylation_extractor output files
and Methpat output files for each sample analyzed in
this paper are available in the GigaScience GigaDB re-
pository [12].re aligned to the hg38 reference genome in bisulfite space. a hg38
ith default parameters. b Bismark is used to align raw reads from
ctor is then used to extract the methylation status of all cytosines
erates on. Methpat requires this file along with a BED formatted
the start and end coordinates of the amplicon and the primer
elimited file containing read counts of DNA methylation patterns
lication quality figures
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BED: Browser extensible data; RRBS: Reduced representation bisulfite
sequencing; WGBS: Whole genome bisulfite sequencing.
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